Blog
RSS FeedPosted by Michael Wonder on 05 Jun 2018
NICE rules against first-line use of Ipsen’s Cabometyx
5 June 2018 - NICE has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on ...
Posted by Michael Wonder on 03 Jun 2018
Tesaro's ovarian cancer drug Zejula added to Cancer Drugs Fund
1 June 2018 - Tesaro's ovarian cancer drug Zejula (niraparib), the first PARP inhibitor shown to be effective in patients ...
Posted by Michael Wonder on 31 May 2018
NHS cancer nurse who crowdfunded her own cancer drug treatment thanks donors for extending her life
31 May 2018 - ‘I would love all drugs to be available on the NHS but it is not a bottomless ...
Posted by Michael Wonder on 31 May 2018
Pfizer's Xalkori makes it onto Cancer Drugs Fund
31 May 2018 - NICE has published draft guidance recommending that Pfizer's Xalkori (crizotinib) to treat ROS1-positive advanced non-small-cell lung ...
Posted by Michael Wonder on 27 May 2018
NICE issues decision on Mylotarg, Besponsa for leukaemia
25 May 2018 - NICE has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid ...
Posted by Michael Wonder on 17 May 2018
NICE backs Roche’s Tecentriq for pre-treated bladder cancer
17 May 2018 - Roche’s Tecentriq will be routinely available on the NHS in England and Wales to patients with ...
Posted by Michael Wonder on 05 May 2018
Hundreds of people with blood cancer given more treatment options after NICE recommends three drugs
4 May 2018 - NICE has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on ...
Posted by Michael Wonder on 05 May 2018
Long term benefit of neuroblastoma treatment is too uncertain, says NICE
4 May 2018 - NICE has published draft guidance in which dinutuximab beta is not recommended as a treatment for high-risk ...
Posted by Michael Wonder on 30 Apr 2018
Final NICE nod for Keytruda in bladder cancer
30 April 2018 - MSD’s Keytruda has become the only immunotherapy to be funded by the NHS for the treatment ...
Posted by Michael Wonder on 11 Apr 2018
Use of Merck's Bavencio (avelumab) on NHS supported by NICE
11 April 2018 - Draft final guidance proposes different access streams for first-line and second-line use in patients with Merkel ...
Posted by Michael Wonder on 09 Apr 2018
NICE u-turn sees Roche’s Tecentriq backed for lung cancer
9 April 2018 - Roche starts the week on a positive note with a NICE recommendation after two rejections from ...
Posted by Michael Wonder on 07 Apr 2018
Roche cops another rejection from NICE
6 April 2018 - Second rebuttal from NICE in as many days. ...
Posted by Michael Wonder on 28 Mar 2018
Final NICE green light for Ipsen’s Cometriq
28 March 2018 - Ipsen’s Cometriq can now be routinely funded by the NHS to treat patients with medullary thyroid ...
Posted by Michael Wonder on 18 Mar 2018
NICE says OK to Keytruda for bladder cancer via the Cancer Drugs Fund
16 March 2018 - Becomes the first immunotherapy recommended for urothelial cancer after chemotherapy. ...
Posted by Michael Wonder on 13 Mar 2018
Cutting-edge NHS drugs do more harm than good
12 March 2018 - Almost all new drugs approved for NHS use do more harm than good, according to modelling ...